RM-718
Congenital hyperinsulinism
Pre-clinicalActive
Key Facts
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals specializes in developing precision medicines for rare diseases of obesity and metabolic dysfunction caused by genetic deficiencies in the melanocortin-4 (MC4) pathway. Their flagship product IMCIVREE represents the first FDA-approved therapy specifically for certain rare genetic obesities, addressing significant unmet medical needs. The company continues to expand the clinical utility of setmelanotide across additional rare obesity syndromes while building a robust pipeline of next-generation therapies.
View full company profileTherapeutic Areas
Other Congenital hyperinsulinism Drugs
| Drug | Company | Phase |
|---|---|---|
| XP-8121 | Xeris Pharmaceuticals | Preclinical/Phase 1 |
| XOMA 358 (RZ358) | XOMA | Phase 2 |
| Ersodetug | Rezolute | Phase 3 |